EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

ESM1 SUMOylation mediates bevacizumab resistance in ovarian cancer through ITGB1-FAK-driven angiogenesis

Xiaomin Ran, Juan Zhang, Juan Yang, Hui Li, Dan Liu, Xing Tang, Wenchao Zhou, Xueru Liu, Yukun Li, Bikang Yang

Cell Reports · 2026

DOI: 10.1016/j.celrep.2026.116927 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cell Reports, 2026. Verfasst von Xiaomin Ran und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gynecologic Oncology Ward 5, Hunan Cancer Hospital, The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South Univers…. Hauptthemen laut MEDLINE: Ovarian Neoplasms, Drug Resistance, Neoplasm, Integrin beta1, Bevacizumab. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 87 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: National Natural Science Foundation of China, Hunan Provincial Natural Science Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Bevacizumab (Bev) resistance limits therapeutic efficacy in ovarian cancer (OC) patients. We identified ESM1 as a key gene in Bev-resistant OC. ESM1 secreted by OC-resistant cell lines activates the ITGB1/FAK axis to induce neovascularization and Bev resistance. Additionally, ESM1 overexpression promoted the growth and Bev resistance of OC, lung, intestinal, and hepatocellular carcinoma tumors. Then, we identified TRIM28 as an upstream regulator that stabilizes ESM1 by promoting SUMOylation, inhibiting its proteasomal degradation. In OC mice, TRIM28 overexpression promotes angiogenesis and Bev resistance via ESM1-mediated ITGB1/FAK activation. This work unveils a new molecular pathway underlying Bev resistance in OC and proposes TRIM28 and ESM1 as potential therapeutic targets.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Ovarian NeoplasmsDrug Resistance, NeoplasmIntegrin beta1BevacizumabNeovascularization, PathologicSumoylationNeoplasm ProteinsProteoglycansFocal Adhesion Kinase 1FemaleHumansAnimalsCell Line, TumorMiceMice, Nude

Stichwörter der Autor:innen

CP: cancerESM1angiogenesisbevacizumabovarian cancerresistant

Substanzen

Integrin beta1BevacizumabNeoplasm ProteinsProteoglycansFocal Adhesion Kinase 1

Autor:innen und Institutionen

  • Department of Gynecologic Oncology Ward 5, Hunan Cancer Hospital, The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, Hunan 410013, China.
  • Department of Assisted Reproductive Centre, Zhuzhou Hospital Affiliated with Xiangya School of Medicine, Central South University, Zhuzhou, Hunan 412007, China.
  • Department of Assisted Reproductive Centre, Zhuzhou Hospital Affiliated with Xiangya School of Medicine, Central South University, Zhuzhou, Hunan 412007, China; Tumor ImmunoMetabolism Institute (TIMI), The Affiliated Zh…
  • Department of Gynecologic Oncology Ward 5, Hunan Cancer Hospital, The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, Hunan 410013, China. Electronic address: yangbikang@hnc…

Förderung

  • National Natural Science Foundation of China
  • Hunan Provincial Natural Science Foundation

Zitieren

APA

Ran, X., Zhang, J., Yang, J., Li, H., Liu, D., Tang, X., Zhou, W., Liu, X., Li, Y., & Yang, B. (2026). ESM1 SUMOylation mediates bevacizumab resistance in ovarian cancer through ITGB1-FAK-driven angiogenesis. Cell Reports. https://doi.org/10.1016/j.celrep.2026.116927

Vancouver

Ran X, Zhang J, Yang J, Li H, Liu D, Tang X, et al. ESM1 SUMOylation mediates bevacizumab resistance in ovarian cancer through ITGB1-FAK-driven angiogenesis. Cell Reports. 2026. doi:10.1016/j.celrep.2026.116927

BibTeX
@article{Ran2026,
  author = {Ran, Xiaomin and Zhang, Juan and Yang, Juan and Li, Hui and Liu, Dan and Tang, Xing and Zhou, Wenchao and Liu, Xueru and Li, Yukun and Yang, Bikang},
  title = {ESM1 SUMOylation mediates bevacizumab resistance in ovarian cancer through ITGB1-FAK-driven angiogenesis},
  journal = {Cell Reports},
  year = {2026},
  doi = {10.1016/j.celrep.2026.116927}
}
Kostenlos starten →